Underlying business recovers, full-year earnings outlook reiterated
29/07/21 -"In its first Litmus test after an ‘ambitious’ CMD in June 2021, the British giant has put up a decent show. The group witnessed recovery in the base business, particularly in vaccines which benefited ..."
Pages
64
Language
English
Published on
29/07/21
You may also be interested by these reports :
10/07/26
Astra’s cardiovascular drug, Wainua, failed a late-stage trial for a heart condition, and most of the drug’s $5bn peak sales expectations hinged on ...
07/07/26
Following the June 2026 phase III R&D setback for an investigational drug, Riliprubart, targeting a rare neurological disease called CIDP (chronic ...
06/07/26
Our target price has been adjusted downward as we have removed the 20% premium associated with peer-based valuation metrics. This adjustment is due ...
30/06/26
The recent US Supreme Court decision in the Roundup litigations, went in favour of Bayer, and brings the firm very close to ending this chapter. Even ...